CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Compared to CP-CML, expression was shown to be further increased in aggressive forms of CML that progressed to blast phase within 3 years and during advanced phases of the disease and was shown to be 2-fold elevated in AP- and BP-CML as compared to CP, both in peripheral blood mononuclear cells and CD34+ cells (Mohty et al., 2007; Saudy et al., 2014).